Shifting the treatment model for resectable pancreatic cancer
Mené sur 93 patients atteints d'un adénocarcinome du pancréas résécable (âge : 18-75 ans), cet essai de phase II/III évalue l'efficacité, du point de vue de la proportion de patients ne connaissant pas d'événement indésirable à 1 an, et la toxicité de diverses chimiothérapies dispensées avant ou après un traitement chirurgical
Historically, patients with pancreatic cancer classified as clearly resectable would, as the nomenclature implies (and almost dictates), be taken immediately to surgery. Over time, however, this treatment model has been gradually shifting as it has become increasingly routine for such patients to initiate systemic therapy as the first step in their care instead of proceeding directly to the operating room. This therapeutic approach is no longer limited exclusively to those individuals with borderline resectable disease, in whom the anatomical connection between tumour and adjacent blood vessels raises concern that negative surgical margins might not be successfully achieved.
The Lancet Gastroenterology & Hepatology , commentaire, 2017